| Name | Title | Contact Details |
|---|
Esaote North America is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We focus on improving the lives of our patients with collaborative care, breakthrough research and by training tomorrow`s physicians. We are University of Minnesota Physicians, the multi-specialty group practice for the University of Minnesota Medical School faculty. As clinicians, we practice in primary care and over 100 specialty and subspecialty areas. As educators, we apply our state-of-the-art knowledge to teach and mentor future physicians. As researchers, we address critical medical problems, then translate our research findings into novel therapies to benefit patients. Our physicians practice academic medicine in an environment of inquiry and education. They work closely with other specialists across disciplines so that our patients receive comprehensive, well-coordinated care tied directly to innovations developed by our research. At UMPhysicians, every employee and physician has a role to play in fostering a culture of integrity and demonstrating our values of Service, Innovation and Respect.
ValenTx was founded with the goal of treating some of the most pervasive health problems of our time: obesity and obesity-related metabolic disorders such as type-2 diabetes and hypertension. Our approach is to create a non-surgical, endoluminal bypass device that builds on the success of established medical interventions, resulting in a highly effective and least-invasive therapy. Current treatments for these diseases include surgery, pharmacology, and medically supervised lifestyle management. The risks, costs, and in some cases poor efficacy of these treatments have hampered their broad adoption by patients, physicians, and payers alike. A truly unmet clinical need exists for a therapy that can deliver the efficacy obtained through surgery, but without the risks and costs associated with surgical intervention. The ValenTx endoluminal bypass therapy mimics the attributes of a Roux-en-Y gastric bypass and is implanted through a non-surgical, endoscopic procedure. This procedure does not require gastric stapling or permanent changes to the patient`s anatomy. The device is removable, replaceable and designed so that the physician could change the therapeutic profile, thereby optimizing the treatment towards the individual patient`s needs. ValenTx has developed a strong intellectual property portfolio, which lies at the foundation of this therapy. The company has successfully conducted a series of clinical studies demonstrating the viability, safety, and efficacy of the therapy.
Dds Lab,Inc is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Oxford Pharmaceutical Resources is a Totowa, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.